Like other GLP-1 medications, semaglutide can cause side effects such as gastrointestinal symptoms and potentially serious risks described in its prescribing information, so it should only be used under the guidance of a licensed healthcare provider
Responsive Support Clear communication and timely assistance when you need it
How It Works Activates both GLP-1 and GIP receptors for a broader metabolic impact Reduces appetite and increases satiety through two hormonal pathways Enhances insulin sensitivity more aggressively than GLP-1 alone Supports reduction of visceral fat the deep abdominal fat most strongly associated with metabolic disease Improves blood sugar regulation through a dual insulin-stimulating mechanism Clinical Results In the SURMOUNT-1 trial, Tirzepatide produced average weight loss of up to 20% of body weight outperforming Semaglutide in head-to-head comparisons
CrossRef Hypoxia upregulates hepatic angiopoietin-2 transcription to promote the progression of hepatocellular carcinoma Jun-Ling Yang, Jie Yang, Rong-Fei Fang, Wen-Li Sai, Deng-Fu Yao, Min Yao World Journal of Hepatology .2024
This distinction matters because it indicates the issue stems from altered motility and fluid absorption rather than any damage to intestinal tissue
While the timeline is consistent across most patients, your metabolic health, medication type, and lifestyle habits determine how quickly changes appear
